Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI

In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.

Clinical Trial Results National Cancer Institute

Revumenib: a new therapy for AML patients

Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022

Edward Carr on LinkedIn: Revumenib Shows Promise for Advanced

MEN1 mutations mediate clinical resistance to menin inhibition

Therapeutic implications of menin inhibition in acute leukemias

Medical Advances in Leukemia Research

Al Giovanniello on LinkedIn: Revumenib Shows Promise for Advanced

Drug 'cures' 33% of patients with aggressive leukaemia in early